The Hôpital Européen Georges-Pompidou is a French hospital located in Paris. The HEGP is under the aegis of the Assistance publique - Hôpitaux de Paris. Opened in 2001, the HEGP is the last-born Parisian hospital resulting from the merger of three older hospitals of the 15th district.

During the past decade, Hôpital Européen Georges Pompidou conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 1 clinical trials were completed, i.e. on average, 14.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Européen Georges Pompidou" #1 sponsor was "Hospices Civils de Lyon" with 2 trials, followed by "Incyte Corporation" with 2 trials sponsored, "Vertex Pharmaceuticals Incorporated" with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Européen Georges Pompidou" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Européen Georges Pompidou" are "Appendiceal Mucinous Neoplasms" (1 trials), "Desmoplastic Small Round Cell Tumor" (1 trials), "Diffuse Peritoneal Leiomyomatosis" (1 trials), "Glomerulosclerosis, Focal Segmental" (1 trials) and "Metastatic Cholangiocarcinoma" (1 trials). Many other conditions were trialed in "Hôpital Européen Georges Pompidou" in a lesser frequency.

Most popular intervention types in "Hôpital Européen Georges Pompidou" are "Drug" (6 trials), "Other" (2 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "VX-147" (2 trials), "5-Fluorouracil" (1 trials), "Avelumab" (1 trials), "Best supportive care" (1 trials) and "Capecitabine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Européen Georges Pompidou" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Hôpital Européen Georges Pompidou". undefined are not yet recruiting, 5 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Hôpital Européen Georges Pompidou, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Européen Georges Pompidou, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".